BioMavericks provides an AI-driven liquid biopsy platform for non-invasive cancer detection and monitoring. The OncoMaverickDX™ platform analyzes mRNA-derived immune signatures in blood samples to rapidly identify cancers with high accuracy, enabling timely treatment decisions and recurrence monitoring.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection and monitoring of cancer are hindered by the limitations of current diagnostic methods, which can be invasive, costly, and time-consuming. This delay in obtaining diagnostic information impacts timely treatment initiation and patient outcomes.
Solution
BioMavericks offers the OncoMaverickDX™ platform, an AI-driven liquid biopsy solution for non-invasive cancer detection and monitoring. The platform analyzes unique immune signatures derived from mRNA in blood samples, leveraging advanced machine learning models to identify cancers with high accuracy. This approach provides rapid, cost-effective diagnostic insights, enabling clinicians to make informed decisions regarding patient care. The system can also monitor treatment response and detect cancer recurrence by analyzing the patient's immune system's activity.
Target Audience
The primary customers are healthcare providers, including oncologists and diagnostic laboratories, seeking advanced, non-invasive tools for early cancer detection, monitoring, and precision medicine.
Features
- AI-powered analysis of mRNA-derived immune signatures for cancer detection.
- Utilizes a QPCR pioneer biomarker assay for rapid results within 4 hours.
- Differentiates from ctDNA and exosome-based methods by focusing on immune response markers.
- Demonstrated ~95% sensitivity and specificity across over 10 cancer types in initial clinical validation.
- Capable of monitoring treatment efficacy and detecting cancer recurrence.
- Employs a Deep Neural Network platform trained on over 20,000 datasets for biomarker discovery.